Genedrive (GB:GDR) has released an update.
Genedrive PLC has announced substantial progress in the UK, with initial orders exceeding £100,000 for their Genedrive MT-RNR1 test from five new hospitals in Greater Manchester. This rapid, non-invasive genetic test, which helps prevent hearing loss in newborns treated with antibiotics in NICUs, is gaining traction following a conditional recommendation from NICE. The company’s CEO expressed optimism for further NHS adoption and growing international opportunities.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.